ADAMTS7 and atrial fibrillation: We have found that 28 days of DOAC therapy marginally decreased ADAMTS7 promoter methylation from baseline in DOAC-treated AF patients and that this effect was statistically significant in patients who reported DOAC-related bleeding events.